Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities    
Net loss $ (41,823) $ (65,354)
Items not involving cash    
Stock-based compensation 5,207 12,949
Shares issued to Hanmi Pharmaceutical as license fees 0 7,500
Depreciation and amortization 120 150
Disposal of property and equipment 16 0
Amortization of right-of-use assets 408 472
Interest on lease liabilities 35 43
Unrealized foreign exchange gain/(loss) 4 (7)
Accrued interest on investments (60) (18)
Change in operating working capital    
Prepaid expenses 173 78
Operating lease payments (546) (555)
Other assets (124) (4)
Accounts payable 4,627 (472)
Accrued liabilities (359) 1,914
Cash used in operating activities (32,322) (43,304)
Cash flows from financing activities    
Issuance of common shares pursuant to exercise of stock options 15 190
Cash provided by financing activities 116 226
Cash flows from (used in) investing activities    
Maturity (acquisition) of investments, net 30,090 (34,996)
Purchase of property and equipment (24) (212)
Cash provided by (used in) investing activities 30,066 (35,208)
Effect of exchange rate fluctuations on cash and cash equivalents held (4) 7
Decrease in cash and cash equivalents (2,144) (78,279)
Cash and cash equivalents, beginning of year 39,114 117,393
Cash and cash equivalents, end of year 36,970 39,114
The 2022 ATM Offering [Member]    
Cash flows from financing activities    
Issuance of common shares 51 0
The 2020 ATM Offering [Member]    
Cash flows from financing activities    
Issuance of common shares $ 50 $ 36